Martin Teichmann

Prof. Martin Teichmann


Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2007 in Trends in Genetics
Verified
Journal Article
Closed access
GIORGIO DIECIGIORGIO DIECI
GIORGIO DIECI
GFGloria Fiorino
Gloria Fiorino
MCManuele Castelnuovo
Manuele Castelnuovo
MTMartin Teichmann
Martin Teichmann
Aldo PaganoAldo Pagano
Aldo Pagano

9 July 2014 in Nature
Verified
Journal Article
Closed access
SWSusanne Walz
Susanne Walz
FLFrancesca Lorenzin
Francesca Lorenzin
JMJennifer P Morton
Jennifer P Morton
KWKatrin E. Wiese
Katrin E. Wiese
BEBjörn von Eyss
Björn von Eyss
MEMartin Eilers
Martin Eilers

8 March 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
GCGrégoire Cullot
Grégoire Cullot
JBJulian Boutin
Julian Boutin
JTJérôme Toutain
Jérôme Toutain
FPFlorence Prat
Florence Prat
PPPerrine Pennamen
Perrine Pennamen
ABAurélie Bedel
Aurélie Bedel
CRISPR-Cas9 is a promising technology for genome editing. Here we use Cas9 nuclease-induced double-strand break DNA (DSB) at the UROS locus to model and correct congenital erythropoietic porphyria. We demonstrate that homology-directed repair is rare compared with NHEJ pathway leading to on-target indels and causing unwanted dysfunctional protein. Moreover, we describe unexpected chromosomal truncations resulting from only one Cas9 nuclease-induced DSB in cell lines and primary cells by a p53-dependent mechanism. Altogether, these side effects may limit the promising perspectives of the CRISPR-Cas9 nuclease system for disease modeling and gene therapy. We show that the single nickase approach could be safer since it prevents on- and off-target indels and chromosomal truncations. These results demonstrate that the single nickase and not the nuclease approach is preferable, not only for modeling disease but also and more importantly for the safe management of future CRISPR-Cas9-mediated gene therapies.

1 September 2011 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
GBGeneviève Bernard
Geneviève Bernard
ECEliane Chouery
Eliane Chouery
MPMaria Lisa Putorti
Maria Lisa Putorti
MTMartine Tétreault
Martine Tétreault
ATAsako Takanohashi
Asako Takanohashi
BBBernard Brais
Bernard Brais

11 May 2001 in Science
Verified
Journal Article
Closed access
PDF file
DZDi Zhang
Di Zhang
TPTarja-Leena Penttila
Tarja-Leena Penttila
PMPatricia L. Morris
Patricia L. Morris
MTMartin Teichmann
Martin Teichmann
RRRobert G. Roeder
Robert G. Roeder
The discovery of TATA-binding protein–related factors (TRFs) has suggested alternative mechanisms for gene-specific transcriptional regulation and raised interest in their biological functions. In contrast to recent observations of an embryonic lethal phenotype for TRF2 inactivation in Caenorhabditis elegans and Xenopus laevis , we found that Trf2 -deficient mice are viable. However, Trf2 –/– mice are sterile because of a severe defect in spermiogenesis. Postmeiotic round spermatids advance at most to step 7 of differentiation but fail to progress to the elongated form, and gene-specific transcription deficiencies were identified. We speculate that mammals may have evolved more specialized TRF2 functions in the testis that involve transcriptional regulation of genes essential for spermiogenesis.

1 November 2011 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
MTMartine Tétreault
Martine Tétreault
KCKarine Choquet
Karine Choquet
SOSimona Orcesi
Simona Orcesi
DTDavide Tonduti
Davide Tonduti
UBUmberto Balottin
Umberto Balottin
GBGeneviève Bernard
Geneviève Bernard